[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Syndax Pharma (SNDX)

Syndax Pharma (SNDX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,890,147
  • Shares Outstanding, K 88,201
  • Annual Sales, $ 172,350 K
  • Annual Income, $ -285,420 K
  • EBIT $ -273 M
  • EBITDA $ -284 M
  • 60-Month Beta 0.41
  • Price/Sales 10.56
  • Price/Cash Flow N/A
  • Price/Book 27.74

Options Overview Details

View History
  • Implied Volatility 87.75% (+16.49%)
  • Historical Volatility 52.24%
  • IV Percentile 62%
  • IV Rank 40.22%
  • IV High 150.01% on 10/16/25
  • IV Low 45.85% on 03/12/26
  • Expected Move (DTE 14) 0.77 (4.00%)
  • Put/Call Vol Ratio 6.18
  • Today's Volume 1,472
  • Volume Avg (30-Day) 757
  • Put/Call OI Ratio 0.29
  • Today's Open Interest 15,000
  • Open Int (30-Day) 13,933
  • Expected Range 18.35 to 19.88

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 14 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $-0.41
  • Number of Estimates 4
  • High Estimate $-0.18
  • Low Estimate $-0.68
  • Prior Year $-0.83
  • Growth Rate Est. (year over year) +50.60%

Price Performance

See More
Period Period Low Period High Performance
1-Month
19.00 +0.58%
on 05/01/26
25.53 -25.15%
on 04/06/26
-4.77 (-19.97%)
since 04/01/26
3-Month
19.00 +0.58%
on 05/01/26
25.59 -25.32%
on 03/25/26
-1.20 (-5.91%)
since 01/30/26
52-Week
8.58 +122.73%
on 05/15/25
25.59 -25.32%
on 03/25/26
+5.29 (+38.28%)
since 05/01/25

Most Recent Stories

More News
Syndax: Q1 Earnings Snapshot

Syndax: Q1 Earnings Snapshot

SNDX : 19.11 (-10.83%)
Syndax Reports First Quarter 2026 Financial Results and Provides Business Update

– Total revenue of $64.9 million in 1Q26, a 224% year-over-year increase – – Revuforj ® (revumenib) net revenue of $48.9 million in 1Q26, highlighting leadership in menin inhibition...

SNDX : 19.11 (-10.83%)
Syndax: When Does the Revenue Ramp Start Covering the Cash Burn Story?

Barchart Research What to Expect from SNDX Earnings SNDX Generated April 29, 2026 Current Price $20.63 EPS Estimate $$-0.58 Consensus Rating Strong Buy Average Move 10.13% Syndax: When Does the Revenue...

SNDX : 19.11 (-10.83%)
Syndax to Announce First Quarter 2026 Financial Results and Host Conference Call and Webcast on April 30, 2026

NEW YORK, April 24, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that it will report...

SNDX : 19.11 (-10.83%)
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

NEW YORK, April 03, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that on April 1,...

SNDX : 19.11 (-10.83%)
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

NEW YORK, March 04, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that on March 1,...

SNDX : 19.11 (-10.83%)
Syndax: Q4 Earnings Snapshot

Syndax: Q4 Earnings Snapshot

SNDX : 19.11 (-10.83%)
Syndax Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

– Total revenue of $68.7 million in 4Q25 and $172.4 million in FY2025 –  – Revuforj ® (revumenib) net revenue of $44.2 million in 4Q25, a 38% increase vs 3Q25, and $124.8 million in FY2025...

SNDX : 19.11 (-10.83%)
Syndax Announces Participation in March Investor Conferences

NEW YORK, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that Michael A....

SNDX : 19.11 (-10.83%)
Syndax to Announce Fourth Quarter and Full Year 2025 Financial Results and Host Conference Call and Webcast on February 26, 2026

NEW YORK, Feb. 19, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that it will report...

SNDX : 19.11 (-10.83%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Buy with a Weakening short term outlook on maintaining the current direction.

Relative Strength just crossed below 30%. The market has entered oversold territory.

See More Share

Business Summary

Syndax Pharmaceuticals, Inc. is a biopharmaceutical company which focused on the development and commercialization of entinostat, an epigenetic therapy for treatment-resistant cancers. The Company's product pipeline includes ENCORE 601, ENCORE 602, J1353, NCI-7870, NCI-9844, E2112, NCI-8871 and NCI-9253...

See More

Key Turning Points

3rd Resistance Point 22.77
2nd Resistance Point 22.00
1st Resistance Point 20.55
Last Price 19.11
1st Support Level 18.33
2nd Support Level 17.56
3rd Support Level 16.11

See More

52-Week High 25.59
Last Price 19.11
Fibonacci 61.8% 19.09
Fibonacci 50% 17.08
Fibonacci 38.2% 15.08
52-Week Low 8.58

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.